市場調査レポート

商品コード

1630625

血友病治療市場規模、シェア、成長分析、タイプ別、薬剤クラス別、治療法別、患者別、治療別、投与経路別、最終用途別、地域別 - 産業予測、2025-2032年

Hemophilia Treatment Market Size, Share, Growth Analysis, By Type, By Drug Class, By Therapy, By Patient, By Treatment, By Route of Administration, By End-use, By Region - Industry Forecast 2025-2032

出版日: 2025年01月09日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 778,146円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 910,284円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,042,422円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.82円

全表示
概要
目次

概要

サンプル依頼リストに入れる

血友病治療の世界市場規模は、2023年に134億米ドルと評価され、2024年の142億8,000万米ドルから2032年には238億2,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは6.6％で成長する見通しです。

世界の血友病治療市場は、医療技術の進歩、疾患に対する意識の高まり、ヘルスケアへのアクセスの改善などを背景に、著しい拡大を遂げています。同市場では、血友病AおよびBの治療に不可欠な遺伝子組換え型血液凝固第VIII因子製剤や血液凝固第IX因子製剤など、多様な製品が提供されています。これらの濃縮製剤は、欠乏している凝固因子を補充することにより、出血リスクを大幅に減少させます。さらに、遺伝子治療は画期的な治療法の可能性を秘めており、血友病の中核をなす遺伝的欠陥の是正を目指しています。主な成長要因としては、血友病の有病率の上昇、ヘルスケア支出の増加、個別化医療へのシフトなどが挙げられます。遺伝子工学とバイオテクノロジーの絶え間ない進化により、市場は血友病の治療成績を向上させ、決定的な治療法を模索するための革新的な治療ソリューションの準備が整っています。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主な市場企業が採用した戦略
市場の最近の動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 会社概要
- 製品ポートフォリオ分析
- セグメント別シェア分析
- 収益の前年比比較（2022-2024）

主要企業プロファイル

Pfizer Inc.（United States）
Bayer AG（Germany）
Novo Nordisk A/S（Denmark）
CSL Behring（Australia）
BioMarin Pharmaceutical Inc.（United States）
Sangamo Therapeutics（United States）
Octapharma AG（Switzerland）
Roche Holding AG（Switzerland）
Sanofi S.A.（France）
Takeda Pharmaceutical Company Limited（Japan）
Grifols S.A.（Spain）
Alnylam Pharmaceuticals, Inc.（United States）
Biogen Inc.（United States）
Kedrion Biopharma（Italy）
SOBI（Sweden）
Genentech, Inc.（United States）
Shire plc（United Kingdom）
Aptevo Therapeutics（United States）
Catalyst Biosciences（United States）
uniQure N.V.（Netherlands）

結論と推奨事項

Product Code: SQMIG35D2171

Global Hemophilia Treatment Market size was valued at USD 13.4 billion in 2023 and is poised to grow from USD 14.28 billion in 2024 to USD 23.82 billion by 2032, growing at a CAGR of 6.6% during the forecast period (2025-2032).

The global Hemophilia Treatment Market has experienced remarkable expansion, driven by medical technology advancements, heightened awareness of the disorder, and improved healthcare access. The market offers a diverse range of products, including clotting factor concentrates like recombinant factor VIII and factor IX, essential for treating hemophilia A and B, respectively. These concentrates significantly decrease bleeding risks by replenishing absent clotting factors. Additionally, gene therapy represents a groundbreaking potential cure, aiming to rectify the genetic defects at the disorder's core. Key growth factors include the rising prevalence of hemophilia, increasing healthcare spending, and a shift towards personalized medicine. With the continuous evolution in genetic engineering and biotechnology, the market is poised for innovative treatment solutions to enhance outcomes and seek definitive cures for hemophilia.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hemophilia Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hemophilia Treatment Market Segmental Analysis

Global Hemophilia Treatment Market is segmented by Type, Drug Class, Therapy, Patient, Treatment, Route of Administration, End-use and region. Based on Type, the market is segmented into Hemophilia A and Hemophilia B. Based on Drug Class, the market is segmented into Vasopressin and Coagulation factors. Based on Therapy, the market is segmented into Recombinant coagulation factor concentrates therapy, Plasma derived coagulation factor concentrates therapy, Non-factor replacement therapy, Extended half-life products, Desmopressin, Antifibrinolytic agents, Gene therapy products and Others. Based on Patient, the market is segmented into Pediatric and Adult. Based on Treatment, the market is segmented into Prophylaxis and On demand. Based on Route of Administration, the market is segmented into Injectable, Nasal spray and Oral. Based on End-use, the market is segmented into Hospitals, Clinics, Hemophilia treatment centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hemophilia Treatment Market

The global Hemophilia Treatment market is primarily driven by continuous technological advancements in the realm of diagnostics and therapies. Leading players in the industry are focused on developing innovative, cutting-edge tools and medications designed to enhance the effectiveness and precision of hemophilia treatment. Furthermore, substantial investments aimed at expanding specialized hemophilia treatment centers (HTCs) worldwide contribute significantly to the positive market outlook. The combination of enhanced technology and the growth of dedicated treatment facilities is expected to propel the market forward, ensuring better patient outcomes and increased accessibility to quality care for individuals living with hemophilia.

Restraints in the Global Hemophilia Treatment Market

The Global Hemophilia Treatment market faces significant restraints due to the stringent regulatory approval processes enforced by health authorities. These rigorous requirements necessitate that manufacturers undergo comprehensive assessments of safety and efficacy, which can be both time-consuming and resource-heavy. As a result, the lengthy approval times can hinder the market entry of innovative treatment options, ultimately stalling growth and limiting patient access to new therapies. This regulatory burden can create barriers for companies seeking to introduce advancements in hemophilia care, thereby impacting the overall development and competitiveness of the market.

Market Trends of the Global Hemophilia Treatment Market

The global hemophilia treatment market is witnessing significant growth driven by an increase in the incidence of genetic disorders and a rising population of hemophiliac patients. Enhanced diagnostic capabilities and growing awareness around preventive treatment options are further propelling market expansion. Major pharmaceutical firms are realizing lucrative opportunities due to heightened diagnosis rates, while regulatory bodies are initiating campaigns to promote early diagnosis and testing for newborns. This awareness boost not only accelerates treatment accessibility but also invigorates research and development efforts, as companies seek innovative solutions amidst a limited therapeutic landscape. Overall, these trends signal a robust growth trajectory for the market.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Technological Advancement

Global Hemophilia Treatment Market Size by Type & CAGR (2025-2032)

Market Overview
Hemophilia A
Hemophilia B

Global Hemophilia Treatment Market Size by Drug Class & CAGR (2025-2032)

Market Overview
Vasopressin
Coagulation factors

Global Hemophilia Treatment Market Size by Therapy & CAGR (2025-2032)

Market Overview
Recombinant coagulation factor concentrates therapy
Plasma derived coagulation factor concentrates therapy
Non-factor replacement therapy
Extended half-life products
Desmopressin
Antifibrinolytic agents
Gene therapy products
Others

Global Hemophilia Treatment Market Size by Patient & CAGR (2025-2032)

Market Overview
Pediatric
Adult

Global Hemophilia Treatment Market Size by Treatment & CAGR (2025-2032)

Market Overview
Prophylaxis
On demand

Global Hemophilia Treatment Market Size by Route of Administration & CAGR (2025-2032)

Market Overview
Injectable
Nasal spray
Oral

Global Hemophilia Treatment Market Size by End-use & CAGR (2025-2032)

Market Overview
Hospitals
Clinics
Hemophilia treatment centers
Others

Global Hemophilia Treatment Market Size & CAGR (2025-2032)

North America (Type, Drug Class, Therapy, Patient, Treatment, Route of Administration, End-use)
- US
- Canada
Europe (Type, Drug Class, Therapy, Patient, Treatment, Route of Administration, End-use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Drug Class, Therapy, Patient, Treatment, Route of Administration, End-use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Drug Class, Therapy, Patient, Treatment, Route of Administration, End-use)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Drug Class, Therapy, Patient, Treatment, Route of Administration, End-use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novo Nordisk A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CSL Behring (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioMarin Pharmaceutical Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sangamo Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Octapharma AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Grifols S.A. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alnylam Pharmaceuticals, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kedrion Biopharma (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SOBI (Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genentech, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shire plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aptevo Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Catalyst Biosciences (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
uniQure N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

血友病治療市場規模、シェア、成長分析、タイプ別、薬剤クラス別、治療法別、患者別、治療別、投与経路別、最終用途別、地域別 - 産業予測、2025-2032年

Hemophilia Treatment Market Size, Share, Growth Analysis, By Type, By Drug Class, By Therapy, By Patient, By Treatment, By Route of Administration, By End-use, By Region - Industry Forecast 2025-2032

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

血友病治療市場規模：タイプ別

血友病治療市場規模：薬剤クラス別

血友病治療市場規模：治療法別

血友病治療市場規模：患者別

血友病治療市場規模：治療別

血友病治療市場規模：投与経路別

血友病治療市場規模：最終用途別

血友病治療市場規模